Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PHARMACOKINETICS, SAFETY AND EFFICACY OF LENALIDOMIDE (REVLIMID) IN COMBINATION WITH DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA AND IMPAIRED RENAL FONCTION.

Next Previous
Search
Trial Profile

PHARMACOKINETICS, SAFETY AND EFFICACY OF LENALIDOMIDE (REVLIMID) IN COMBINATION WITH DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA AND IMPAIRED RENAL FONCTION.

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Jul 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Pharmacokinetics
  • Acronyms REVIR

    • Most Recent Events

    • 11 Dec 2011 Status changed from recruiting to active, no longer recruiting. Overall, 37 patients were recruited and 10 months follow-up completed.
    • 11 Dec 2011 Results were reported at the 53rd Annual Meeting and Exposition of the American Society of Hematology.
    • 29 Jul 2011 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top